methylation pyrosequencing analyses Search Results


86
Pyrosequencing Inc pyrosequencing based methylation analysis pma
Pyrosequencing Based Methylation Analysis Pma, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/methylation+pyrosequencing+analyses/analysis+based+methylation+pyrosequencing/pm34432028-108-2-2
Average 86 stars, based on 1 article reviews
pyrosequencing based methylation analysis pma - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

90
BIOTAGE pyromark id96 system
Pyromark Id96 System, supplied by BIOTAGE, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/methylation+pyrosequencing+analyses/pyromark+id96+system/pmc04496338-146-11-14
Average 90 stars, based on 1 article reviews
pyromark id96 system - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

86
Pyrosequencing Inc bisulfite pyrosequencing
Bisulfite Pyrosequencing, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/methylation+pyrosequencing+analyses/bisulfite+pyrosequencing/10__1530_slash_etj___24___0080-6-5-6
Average 86 stars, based on 1 article reviews
bisulfite pyrosequencing - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Pyrosequencing Inc mlh1 promoter methylation analysis
Representative images of an EC with <t>MLH1</t> deficiency, absence of MLH1 promoter <t>methylation,</t> and positive EPM2 AIP1 immunostaining. The tumor exhibited biallelic somatic alteration of MLH1 ; one pathogenic variant in MLH1 ( NM_000249.4 ): p.Glu633 Ter (c.1897G > T), classified as a stop-gained mutation, truncating the <t>MLH1</t> <t>protein,</t> as well as loss of heterozygosity (LOH) detected in chromosomal region 3p22.2-q27.1
Mlh1 Promoter Methylation Analysis, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/methylation+pyrosequencing+analyses/analysis+methylation+pyrosequencing+quantitative+universal/pmc12488810-246-6-11
Average 86 stars, based on 1 article reviews
mlh1 promoter methylation analysis - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

90
BIOTAGE pyrosequencing assay design software 1.0.6
Representative images of an EC with <t>MLH1</t> deficiency, absence of MLH1 promoter <t>methylation,</t> and positive EPM2 AIP1 immunostaining. The tumor exhibited biallelic somatic alteration of MLH1 ; one pathogenic variant in MLH1 ( NM_000249.4 ): p.Glu633 Ter (c.1897G > T), classified as a stop-gained mutation, truncating the <t>MLH1</t> <t>protein,</t> as well as loss of heterozygosity (LOH) detected in chromosomal region 3p22.2-q27.1
Pyrosequencing Assay Design Software 1.0.6, supplied by BIOTAGE, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/methylation+pyrosequencing+analyses/pyrosequencing+assay+design+software/pmc06887740-207-10-14
Average 90 stars, based on 1 article reviews
pyrosequencing assay design software 1.0.6 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

86
Pyrosequencing Inc methylation analysis
Representative images of an EC with <t>MLH1</t> deficiency, absence of MLH1 promoter <t>methylation,</t> and positive EPM2 AIP1 immunostaining. The tumor exhibited biallelic somatic alteration of MLH1 ; one pathogenic variant in MLH1 ( NM_000249.4 ): p.Glu633 Ter (c.1897G > T), classified as a stop-gained mutation, truncating the <t>MLH1</t> <t>protein,</t> as well as loss of heterozygosity (LOH) detected in chromosomal region 3p22.2-q27.1
Methylation Analysis, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/methylation+pyrosequencing+analyses/analysis+methylation/10__1183_slash_23120541__01285___2025-280-1-0
Average 86 stars, based on 1 article reviews
methylation analysis - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

90
imaGenes GmbH medip-chip analysis
Representative images of an EC with <t>MLH1</t> deficiency, absence of MLH1 promoter <t>methylation,</t> and positive EPM2 AIP1 immunostaining. The tumor exhibited biallelic somatic alteration of MLH1 ; one pathogenic variant in MLH1 ( NM_000249.4 ): p.Glu633 Ter (c.1897G > T), classified as a stop-gained mutation, truncating the <t>MLH1</t> <t>protein,</t> as well as loss of heterozygosity (LOH) detected in chromosomal region 3p22.2-q27.1
Medip Chip Analysis, supplied by imaGenes GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/methylation+pyrosequencing+analyses/medip+chip+analysis/pm28373690-91-18-33
Average 90 stars, based on 1 article reviews
medip-chip analysis - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
BIOTAGE pyrosequencing psq 96ma
Representative images of an EC with <t>MLH1</t> deficiency, absence of MLH1 promoter <t>methylation,</t> and positive EPM2 AIP1 immunostaining. The tumor exhibited biallelic somatic alteration of MLH1 ; one pathogenic variant in MLH1 ( NM_000249.4 ): p.Glu633 Ter (c.1897G > T), classified as a stop-gained mutation, truncating the <t>MLH1</t> <t>protein,</t> as well as loss of heterozygosity (LOH) detected in chromosomal region 3p22.2-q27.1
Pyrosequencing Psq 96ma, supplied by BIOTAGE, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/methylation+pyrosequencing+analyses/psq96ma+system/pmc03742793-38-9-11
Average 90 stars, based on 1 article reviews
pyrosequencing psq 96ma - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

96
Zymo Research ez methylation kit
Representative images of an EC with <t>MLH1</t> deficiency, absence of MLH1 promoter <t>methylation,</t> and positive EPM2 AIP1 immunostaining. The tumor exhibited biallelic somatic alteration of MLH1 ; one pathogenic variant in MLH1 ( NM_000249.4 ): p.Glu633 Ter (c.1897G > T), classified as a stop-gained mutation, truncating the <t>MLH1</t> <t>protein,</t> as well as loss of heterozygosity (LOH) detected in chromosomal region 3p22.2-q27.1
Ez Methylation Kit, supplied by Zymo Research, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/methylation+pyrosequencing+analyses/EZ-96+DNA+Methylation+Kit+(Deep-Well)/pmc05930017-120-11-9
Average 96 stars, based on 1 article reviews
ez methylation kit - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

99
Zymo Research ez dna methylation gold kit
Representative images of an EC with <t>MLH1</t> deficiency, absence of MLH1 promoter <t>methylation,</t> and positive EPM2 AIP1 immunostaining. The tumor exhibited biallelic somatic alteration of MLH1 ; one pathogenic variant in MLH1 ( NM_000249.4 ): p.Glu633 Ter (c.1897G > T), classified as a stop-gained mutation, truncating the <t>MLH1</t> <t>protein,</t> as well as loss of heterozygosity (LOH) detected in chromosomal region 3p22.2-q27.1
Ez Dna Methylation Gold Kit, supplied by Zymo Research, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/methylation+pyrosequencing+analyses/EZ+DNA+Methylation-Gold+Kit/pmc04169062-131-13-17
Average 99 stars, based on 1 article reviews
ez dna methylation gold kit - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

90
LEAD Technologies spss v14
Representative images of an EC with <t>MLH1</t> deficiency, absence of MLH1 promoter <t>methylation,</t> and positive EPM2 AIP1 immunostaining. The tumor exhibited biallelic somatic alteration of MLH1 ; one pathogenic variant in MLH1 ( NM_000249.4 ): p.Glu633 Ter (c.1897G > T), classified as a stop-gained mutation, truncating the <t>MLH1</t> <t>protein,</t> as well as loss of heterozygosity (LOH) detected in chromosomal region 3p22.2-q27.1
Spss V14, supplied by LEAD Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/methylation+pyrosequencing+analyses/spss+v14/pmc02427301-124-13-14
Average 90 stars, based on 1 article reviews
spss v14 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

86
Pyrosequencing Inc dna methylation analysis
Epigenetic Changes in Gene Expression — This figure illustrates two key epigenetic mechanisms that regulate gene expression: <t>DNA</t> <t>methylation</t> and histone modifications. DNA methylation involves the addition of methyl groups to the promoter region of a gene, inhibiting transcription and leading to gene silencing. Histone modifications, including acetylation and methylation, alter chromatin structure and gene accessibility; acetylation relaxes chromatin, promoting gene activation, while methylation can either enhance or suppress transcription depending on its context. These epigenetic modifications are dynamic and influenced by environmental factors, such as diet, with implications for metabolism, inflammation, and disease susceptibility.
Dna Methylation Analysis, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/methylation+pyrosequencing+analyses/analysis+dna+methylation/pmc12535778-2-5-11
Average 86 stars, based on 1 article reviews
dna methylation analysis - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

Image Search Results


Representative images of an EC with MLH1 deficiency, absence of MLH1 promoter methylation, and positive EPM2 AIP1 immunostaining. The tumor exhibited biallelic somatic alteration of MLH1 ; one pathogenic variant in MLH1 ( NM_000249.4 ): p.Glu633 Ter (c.1897G > T), classified as a stop-gained mutation, truncating the MLH1 protein, as well as loss of heterozygosity (LOH) detected in chromosomal region 3p22.2-q27.1

Journal: Virchows Archiv

Article Title: EPM2 AIP1 immunohistochemistry as a surrogate of promoter methylation analysis in endometrial carcinoma

doi: 10.1007/s00428-025-04132-3

Figure Lengend Snippet: Representative images of an EC with MLH1 deficiency, absence of MLH1 promoter methylation, and positive EPM2 AIP1 immunostaining. The tumor exhibited biallelic somatic alteration of MLH1 ; one pathogenic variant in MLH1 ( NM_000249.4 ): p.Glu633 Ter (c.1897G > T), classified as a stop-gained mutation, truncating the MLH1 protein, as well as loss of heterozygosity (LOH) detected in chromosomal region 3p22.2-q27.1

Article Snippet: In summary, results show concordance between MLH1 promoter methylation analysis by pyrosequencing and EPM2 AIP1 IHC, with 100% EPM2 AIP1 negativity in the 70 cases that exhibited MLH1 promoter methylation by pyrosequencing.

Techniques: Methylation, Immunostaining, Variant Assay, Mutagenesis

Representative images of an EC with MLH1 with a methylation score close to the cut-off. The initial biopsy A showed negative EPM2 AIP1 immunostaining and a methylation score of 9.8. In the surgical specimen B , EPM2 AIP1 immunostaining was negative, but the methylation score increased to 60% after tumor microdissection

Journal: Virchows Archiv

Article Title: EPM2 AIP1 immunohistochemistry as a surrogate of promoter methylation analysis in endometrial carcinoma

doi: 10.1007/s00428-025-04132-3

Figure Lengend Snippet: Representative images of an EC with MLH1 with a methylation score close to the cut-off. The initial biopsy A showed negative EPM2 AIP1 immunostaining and a methylation score of 9.8. In the surgical specimen B , EPM2 AIP1 immunostaining was negative, but the methylation score increased to 60% after tumor microdissection

Article Snippet: In summary, results show concordance between MLH1 promoter methylation analysis by pyrosequencing and EPM2 AIP1 IHC, with 100% EPM2 AIP1 negativity in the 70 cases that exhibited MLH1 promoter methylation by pyrosequencing.

Techniques: Methylation, Immunostaining, Laser Capture Microdissection

Epigenetic Changes in Gene Expression — This figure illustrates two key epigenetic mechanisms that regulate gene expression: DNA methylation and histone modifications. DNA methylation involves the addition of methyl groups to the promoter region of a gene, inhibiting transcription and leading to gene silencing. Histone modifications, including acetylation and methylation, alter chromatin structure and gene accessibility; acetylation relaxes chromatin, promoting gene activation, while methylation can either enhance or suppress transcription depending on its context. These epigenetic modifications are dynamic and influenced by environmental factors, such as diet, with implications for metabolism, inflammation, and disease susceptibility.

Journal: Gastroenterology and Hepatology From Bed to Bench

Article Title: The epigenetic influence of diet-induced gut microbiome changes in precision nutrition – a systematic review

doi: 10.22037/ghfbb.v18i3.3136

Figure Lengend Snippet: Epigenetic Changes in Gene Expression — This figure illustrates two key epigenetic mechanisms that regulate gene expression: DNA methylation and histone modifications. DNA methylation involves the addition of methyl groups to the promoter region of a gene, inhibiting transcription and leading to gene silencing. Histone modifications, including acetylation and methylation, alter chromatin structure and gene accessibility; acetylation relaxes chromatin, promoting gene activation, while methylation can either enhance or suppress transcription depending on its context. These epigenetic modifications are dynamic and influenced by environmental factors, such as diet, with implications for metabolism, inflammation, and disease susceptibility.

Article Snippet: Sun, et al. (21) , DNA methylation analysis (DREAM sequencing, bisulfite pyrosequencing, qRT-PCR) in a microbiota-inflammation model. , Difficulty separating inflammation’s role in epigenetic changes. , Microbiota and inflammation influenced DNA methylation at CpG sites. , DNA methylation at CpG sites. , Not assessed. , Multi-model approach, deep-sequencing of methylation changes. , Moderate , 2023.

Techniques: Gene Expression, DNA Methylation Assay, Methylation, Activation Assay

Epigenetic Modifications in Metabolic Health and Disease Prevention – This figure illustrates the impact of diet-induced changes in gut microbiome composition on epigenetic modifications and their subsequent effects on metabolic health. The dietary components, such as fiber-rich, polyphenol-rich, and high-fat diets, are shown to influence microbiome diversity and promote the production of metabolites like short-chain fatty acids (SCFAs), which modulate epigenetic markers (e.g., DNA methylation, histone modifications) and gene expression related to inflammation, metabolism, and disease susceptibility. Diets rich in fiber and polyphenols are associated with beneficial microbiome shifts and favorable epigenetic modifications that support metabolic health and reduce the risk of metabolic diseases like obesity and insulin resistance. In contrast, Western-style diets high in fat and processed foods contribute to dysbiosis, inflammation, and adverse epigenetic changes, which may increase the risk of developing chronic metabolic disorders, including obesity and type 2 diabetes.

Journal: Gastroenterology and Hepatology From Bed to Bench

Article Title: The epigenetic influence of diet-induced gut microbiome changes in precision nutrition – a systematic review

doi: 10.22037/ghfbb.v18i3.3136

Figure Lengend Snippet: Epigenetic Modifications in Metabolic Health and Disease Prevention – This figure illustrates the impact of diet-induced changes in gut microbiome composition on epigenetic modifications and their subsequent effects on metabolic health. The dietary components, such as fiber-rich, polyphenol-rich, and high-fat diets, are shown to influence microbiome diversity and promote the production of metabolites like short-chain fatty acids (SCFAs), which modulate epigenetic markers (e.g., DNA methylation, histone modifications) and gene expression related to inflammation, metabolism, and disease susceptibility. Diets rich in fiber and polyphenols are associated with beneficial microbiome shifts and favorable epigenetic modifications that support metabolic health and reduce the risk of metabolic diseases like obesity and insulin resistance. In contrast, Western-style diets high in fat and processed foods contribute to dysbiosis, inflammation, and adverse epigenetic changes, which may increase the risk of developing chronic metabolic disorders, including obesity and type 2 diabetes.

Article Snippet: Sun, et al. (21) , DNA methylation analysis (DREAM sequencing, bisulfite pyrosequencing, qRT-PCR) in a microbiota-inflammation model. , Difficulty separating inflammation’s role in epigenetic changes. , Microbiota and inflammation influenced DNA methylation at CpG sites. , DNA methylation at CpG sites. , Not assessed. , Multi-model approach, deep-sequencing of methylation changes. , Moderate , 2023.

Techniques: DNA Methylation Assay, Gene Expression, Western Blot